Race-linked differences in serum concentrations of dapsone, monoacetyldapsone and pyrimethamine during malaria prophylaxis.
Serum concentrations of dapsone (DDS), monoacetyldapsone (MADDS), the principal acetylated metabolite of DDS, and pyrimethamine (PYR) were measured in 55 Caucasian adults (31 males, 24 females) and 159 Papua New Guinean adults (140 males, 19 females) following the oral administration of Folaprim (100mg DDS; 12.5mg PYR). Blood samples were collected at mean sampling times of eight hours after medication and 18 hours before the next weekly dose for malaria prophylaxis. Clearance of DDS and MADDS from serum were significantly faster (p less than 0.001) in Caucasians than in Papua New Guineans. Significantly lower (p less than greater 0.001) serum concentrations of PYR were found in Papua New Guineans than in Caucasians at both sampling times, an observation which may reflect differences in the bioavailability of PYR between the two racial groups. The theoretical implications of these results are that Caucasians may be more susceptible to PYR-resistant Plasmodium falciparum malaria than Papua New Guineans whilst Papua New Guineans may be more susceptible to P. vivax; malaria than Caucasians.
Cook
I F
IF
Cochrane
J P
JP
Edstein
M D
MD
D000293:Adolescent; D000328:Adult; D001682:Biological Availability; D044383:Black People; D003622:Dapsone / Q000031:analogs & derivatives / Q000097:blood* / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008288:Malaria / Q000097:blood* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010219:Papua New Guinea; D010963:Plasmodium falciparum; D011739:Pyrimethamine / Q000097:blood* / Q000627:therapeutic use; D044465:White People
D004338:Drug Combinations; C001678:Maloprim; D003622:Dapsone; C018965:monoacetyldapsone; D011739:Pyrimethamine